pSivida (NASDAQ: EYPT) is one of 24 public companies in the “Analytical instruments” industry, but how does it contrast to its peers? We will compare pSivida to related companies based on the strength of its risk, profitability, valuation, dividends, institutional ownership, analyst recommendations and earnings.
Insider & Institutional Ownership
8.8% of pSivida shares are owned by institutional investors. Comparatively, 57.8% of shares of all “Analytical instruments” companies are owned by institutional investors. 3.5% of pSivida shares are owned by company insiders. Comparatively, 13.2% of shares of all “Analytical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This table compares pSivida and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|pSivida||$7.54 million||-$18.48 million||-3.69|
|pSivida Competitors||$1.09 billion||$107.48 million||22.78|
pSivida’s peers have higher revenue and earnings than pSivida. pSivida is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This is a summary of current ratings for pSivida and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
pSivida currently has a consensus target price of $7.29, suggesting a potential upside of 279.46%. As a group, “Analytical instruments” companies have a potential upside of 11.48%. Given pSivida’s stronger consensus rating and higher probable upside, research analysts clearly believe pSivida is more favorable than its peers.
This table compares pSivida and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
pSivida has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, pSivida’s peers have a beta of 1.11, suggesting that their average share price is 11% more volatile than the S&P 500.
pSivida peers beat pSivida on 10 of the 13 factors compared.
EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, engages in developing and commercializing ophthalmic products in indications with high unmet medical need to help improve the lives of patients with eye disorders. The company has developed three FDA-approved sustained-release treatments in ophthalmology, including DEXYCU (dexamethasone intraocular suspension), which is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation; ILUVIEN (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis. Its lead product candidate is Durasert, (fluocinolone acetonide intravitreal implant), a micro-insert for the treatment of non-infectious uveitis affecting the posterior segment of the eye. In addition, the company's pre-clinical development program focuses on using its core Durasert platform technology to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. It has license agreements with Bausch and Lomb for Retisert product; a license agreement with Alimera for ocular applications of the ILUVIEN device; and a collaboration agreement with Pfizer for the Durasert device delivering latanoprost. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for pSivida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida and related companies with MarketBeat.com's FREE daily email newsletter.